|
1
|
Trinchieri G: Biology of natural killer
cells. Adv Immunol. 47:187–376. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lanier LL: NK cell recognition. Annu Rev
Immunol. 23:225–274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Caligiuri MA: Human natural killer cells.
Blood. 112:461–469. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Long EO: Regulation of immune responses
through inhibitory receptors. Annu Rev Immunol. 17:875–904. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Formenti SC and Demaria S: Systemic
effects of local radiotherapy. Lancet Oncol. 10:718–726. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Park B, Yee C and Lee KM: The effect of
radiation on the immune response to cancers. Int J Mol Sci.
15:927–943. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friedman EJ: Immune modulation by ionizing
radiation and its implications for cancer immunotherapy. Curr Pharm
Des. 8:1765–1780. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Demaria S and Formenti SC: Role of T
lymphocytes in tumor response to radiotherapy. Front Oncol.
2:952012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim JY, Son YO, Park SW, Bae JH, Chung JS,
Kim HH, Chung BS, Kim SH and Kang CD: Increase of NKG2D ligands and
sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat
shock and ionizing radiation. Exp Mol Med. 38:474–484. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
González S, López-Soto A, Suarez-Alvarez
B, López-Vázquez A and López-Larrea C: NKG2D ligands: key targets
of the immune response. Trends Immunol. 29:397–403. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ames E, Canter RJ, Grossenbacher SK, Mac
S, Smith RC, Monjazeb AM, Chen M and Murphy WJ: Enhanced targeting
of stem-like solid tumor cells with radiation and natural killer
cells. Oncoimmunology. 4:e10362122015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sulica A, Morel P, Metes D and Herberman
RB: Ig-binding receptors on human NK cells as effector and
regulatory surface molecules. Int Rev Immunol. 20:371–414. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schlessinger J: Cell signaling by receptor
tyrosine kinases. Cell. 103:211–225. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mendelsohn J and Baselga J: The EGF
receptor family as targets for cancer therapy. Oncogene.
19:6550–6565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hynes NE and Lane HA: ERBB receptors and
cancer: The complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37 (Suppl 4):S9–S15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Graham J, Muhsin M and Kirkpatrick P:
Cetuximab. Nat Rev Drug Discov. 3:549–550. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sotelo Lezama MJ, Sastre Valera J and
Diaz-Rubio Garcia E: Impact of cetuximab in current treatment of
metastatic colorectal cancer. Expert Opin Biol Ther. 14:387–399.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fang F, Xiao W and Tian Z: NK cell-based
immunotherapy for cancer. Semin Immunol. 31:37–54. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheng M, Chen Y, Xiao W, Sun R and Tian Z:
NK cell-based immunotherapy for malignant diseases. Cell Mol
Immunol. 10:230–252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lim SA, Kim TJ, Lee JE, Sonn CH, Kim K,
Kim J, Choi JG, Choi IK, Yun CO, Kim JH, et al: Ex vivo expansion
of highly cytotoxic human NK cells by cocultivation with irradiated
tumor cells for adoptive immunotherapy. Cancer Res. 73:2598–2607.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gong W, Xiao W, Hu M, Weng X, Qian L, Pan
X and Ji M: Ex vivo expansion of natural killer cells with high
cytotoxicity by K562 cells modified to co-express major
histocompatibility complex class I chain-related protein A, 4-1BB
ligand, and interleukin-15. Tissue Antigens. 76:467–475. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujisaki H, Kakuda H, Shimasaki N, Imai C,
Ma J, Lockey T, Eldridge P, Leung WH and Campana D: Expansion of
highly cytotoxic human natural killer cells for cancer cell
therapy. Cancer Res. 69:4010–4017. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Denman CJ, Senyukov VV, Somanchi SS,
Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN,
Huls MH, et al: Membrane-bound IL-21 promotes sustained ex vivo
proliferation of human natural killer cells. PLoS One.
7:e302642012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Berg M, Lundqvist A, McCoy P Jr, Samsel L,
Fan Y, Tawab A and Childs R: Clinical-grade ex vivo-expanded human
natural killer cells up-regulate activating receptors and death
receptor ligands and have enhanced cytolytic activity against tumor
cells. Cytotherapy. 11:341–355. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee HR, Son CH, Koh EK, Bae JH, Kang CD,
Yang K and Park YS: Expansion of cytotoxic natural killer cells
using irradiated autologous peripheral blood mononuclear cells and
anti-CD16 antibody. Sci Rep. 7:110752017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Beano A, Signorino E, Evangelista A, Brusa
D, Mistrangelo M, Polimeni MA, Spadi R, Donadio M, Ciuffreda L and
Matera L: Correlation between NK function and response to
trastuzumab in metastatic breast cancer patients. J Transl Med.
6:252008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cartron G, Dacheux L, Salles G,
Solal-Celigny P, Bardos P, Colombat P and Watier H: Therapeutic
activity of humanized anti-CD20 monoclonal antibody and
polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood.
99:754–758. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Veluchamy JP, Spanholtz J, Tordoir M,
Thijssen VL, Heideman DA, Verheul HM, de Gruijl TD and van der
Vliet HJ: Combination of NK cells and cetuximab to enhance
anti-tumor responses in RAS mutant metastatic colorectal cancer.
PLoS One. 11:e01578302016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cerboni C, Zingoni A, Cippitelli M,
Piccoli M, Frati L and Santoni A: Antigen-activated human T
lymphocytes express cell-surface NKG2D ligands via an
ATM/ATR-dependent mechanism and become susceptible to autologous
NK-cell lysis. Blood. 110:606–615. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang H, Ruan Z, Wang Y, Han J, Fu X, Zhao
T, Yang D, Xu W, Yang Z, Wang L, et al: MHC class I chain-related
molecules induced on monocytes by IFN-gamma promote NK cell
activation. Mol Immunol. 45:1548–1556. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Veluchamy JP, Lopez-Lastra S, Spanholtz J,
Bohme F, Kok N, Heideman DA, Verheul HM, Di Santo JP, de Gruijl TD
and van der Vliet HJ: In vivo efficacy of umbilical cord blood stem
cell-derived NK cells in the treatment of metastatic colorectal
cancer. Front Immunol. 8:872017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Canter RJ, Grossenbacher SK, Foltz JA,
Sturgill IR, Park JS, Luna JI, Kent MS, Culp WTN, Chen M, Modiano
JF, et al: Radiotherapy enhances natural killer cell cytotoxicity
and localization in pre-clinical canine sarcomas and first-in-dog
clinical trial. J Immunother Cancer. 5:982017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gasser S, Orsulic S, Brown EJ and Raulet
DH: The DNA damage pathway regulates innate immune system ligands
of the NKG2D receptor. Nature. 436:1186–1190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cerboni C, Fionda C, Soriani A, Zingoni A,
Doria M, Cippitelli M and Santoni A: The DNA damage response: A
common pathway in the regulation of NKG2D and DNAM-1 ligand
expression in normal, infected, and cancer cells. Front Immunol.
4:5082014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kute TE, Savage L, Stehle JR Jr,
Kim-Shapiro JW, Blanks MJ, Wood J and Vaughn JP: Breast tumor cells
isolated from in vitro resistance to trastuzumab remain sensitive
to trastuzumab anti-tumor effects in vivo and to ADCC killing.
Cancer Immunol Immunother. 58:1887–1896. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Malmberg KJ, Carlsten M, Björklund A,
Sohlberg E, Bryceson YT and Ljunggren HG: Natural killer
cell-mediated immunosurveillance of human cancer. Semin Immunol.
31:20–29. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang Y, Lim O, Kim TM, Ahn YO, Choi H,
Chung H, Min B, Her JH, Cho SY, Keam B, et al: Phase I study of
random healthy donor-derived allogeneic natural killer cell therapy
in patients with malignant lymphoma or advanced solid tumors.
Cancer Immunol Res. 4:215–224. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ishikawa E, Tsuboi K, Saijo K, Harada H,
Takano S, Nose T and Ohno T: Autologous natural killer cell therapy
for human recurrent malignant glioma. Anticancer Res. 24:1861–1871.
2004.PubMed/NCBI
|
|
41
|
Sakamoto N, Ishikawa T, Kokura S, Okayama
T, Oka K, Ideno M, Sakai F, Kato A, Tanabe M, Enoki T, et al: Phase
I clinical trial of autologous NK cell therapy using novel
expansion method in patients with advanced digestive cancer. J
Transl Med. 13:2772015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Masuyama J, Murakami T, Iwamoto S and
Fujita S: Ex vivo expansion of natural killer cells from human
peripheral blood mononuclear cells co-stimulated with anti-CD3 and
anti-CD52 monoclonal antibodies. Cytotherapy. 18:80–90. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ishikawa T, Okayama T, Sakamoto N, Ideno
M, Oka K, Enoki T, Mineno J, Yoshida N, Katada K, Kamada K, et al:
Phase I clinical trial of adoptive transfer of expanded natural
killer cells in combination with IgG1 antibody in patients with
gastric or colorectal cancer. Int J Cancer. 142:2599–2609. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hashimoto K, Nishimura S, Ito T, Kakinoki
R and Akagi M: Immunohistochemical expression and
clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and
MAGE-A4 expression in highly aggressive soft tissue sarcomas. Eur J
Histochem. 66:33932022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C,
Peng J, Gao L, Liang X and Ma C: Increased expression of programmed
cell death protein 1 on NK cells inhibits NK-cell-mediated
anti-tumor function and indicates poor prognosis in digestive
cancers. Oncogene. 36:6143–6153. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Boerman GH, van Ostaijen-ten Dam MM, Kraal
KC, Santos SJ, Ball LM, Lankester AC, Schilham MW, Egeler RM and
van Tol MJ: Role of NKG2D, DNAM-1 and natural cytotoxicity
receptors in cytotoxicity toward rhabdomyosarcoma cell lines
mediated by resting and IL-15-activated human natural killer cells.
Cancer Immunol Immunother. 64:573–583. 2015. View Article : Google Scholar : PubMed/NCBI
|
